MeMed Diagnostics Overview
MeMed Diagnostics has developed and validated an immune-based protein signature, MeMed BV, which distinguishes between bacterial and viral infections, providing a powerful tool in the fight against resistant strains of bacteria. An ELISA format of MeMed BV called ImmunoXpert is cleared for use in the EU (CE-IVD), Switzerland, and Israel and is currently in pilot distribution in these areas. MeMed is also developing MeMed Key, a platform that paves the way for measuring multiple proteins and signatures, both conventional and innovative, with central lab precision at the point of care. MeMed Key will measure MeMed BV within minutes. In September 2021, the company was granted 510(k) clearance by the FDA for MeMed BV for adults and children.
Cumulative Funding Raised Over Time ($)
$6.3MAug 2013
$33.3MAug 2015
$126.3MAug 2021
$128.7MSep 2011
$198.7MSep 2018
Latest News
Investegate MeMed Announcements MeMed: Maccabi Healthcare Services announces it is the first HMO in the world to include MeMed BV® test as part of routine care
growth-positive
MeMed raises $93 million to translate the immune system
Israeli healthtech company MeMed has completed a $93 million Series E funding round, bringing its total funding to over $200 million. The funding round included new and existing investors, and the companys valuation has significantly increased. MeMed recently received FDA approval for its MeMed BV test, which helps healthcare providers distinguish between bacterial and viral infections. The company plans to focus on manufacturing in the U.S. and Europe, commercializing its product, and expanding its range of diagnostic solutions. MeMed was founded in 2009 and employs 100 people in Israel, Europe, and the U.S.
Investment
growth-positive
Israeli Firm MeMed Receives FDA Clearance For Infection Test
MeMed Diagnostics has received 510(k) clearance from the FDA for its test, MeMed BV, which can distinguish between bacterial and viral infections. The test analyzes the bodys immune response to infection, allowing for better-informed antibiotic treatment decisions. The FDA clearance is a breakthrough moment for MeMed and its host-response technology. The company plans to ramp up commercial activities in the US to ensure broad availability of its products.
Customers
growth-positive
MeMed's Covid-19 severity test receives its CE Mark to predict severe outcomes
Israeli diagnostic tool company MeMed has received the CE Mark in Europe for its new disease management solution called MeMed Covid-19 Severity. The solution uses machine learning to stratify the risk of severe outcomes from the disease. MeMed aims to help physicians identify Covid-19 patients at risk of severe outcomes and manage future pandemics. The companys long-term vision is to transform the way infections are detected and managed by harnessing the power of the host immune response. MeMed Covid-19 Severity will be available in Europe directly from MeMed and through commercial channels. MeMed has received $130 million in fundraising and grants from investors including the European Innovation Council and OurCrowd.
CustomersPartners
growth-positive
MeMed פיתחה בדיקה שתנבא האם מצבו של חולה קורונה עומד להחמיר
Israeli company MeMed, co-founded by Dr. Eran Eden and Dr. Kfir Oved, has developed a new capability to predict which COVID-19 patients are likely to deteriorate into severe illness. The company reads this information from the immune system response and is the only company currently doing so. MeMeds product is already approved for use in Israel and Europe and is nearing the end of a clinical trial for FDA approval. The company has raised around $100 million in funding and plans to grow by 30-40% in the coming year.
InvestmentExpand
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $223.43M |
| Last funding | $93M |
| Stage | E |
| Rounds | 11 |
| Investors | 11 |
Team Members
5
Employees: 51-200
Web & Social Links
| Website | www.me-med.com |
| Careers | Careers page |
Locations
Nahum Het St 5, Tirat Carmel, Israel
Photos & Videos
1 item(s)
MeMed Diagnostics Business
Business models
B2B
Product stage
Released
Employees
51-200
Sector
Health Tech & Life SciencesDigital HealthcareDigital Medical DiagnosticsMedical Decision SupportMedical DevicesDiagnostics DevicesTarget Customer
Healthcare & Life SciencesHealthcareLaboratoriesProvidersCore Technology
Artificial IntelligenceMachine LearningTags (19)
bioconvergenceinflammatory-diseaseshealthcare-providersmedical-devicesdiagnosticsinfectious-diseaselaboratoriesimmunologypersonalized-medicineartificial-intelligencedecision-makingdigital-healthcarebacteriabioinformaticsmachine-learningbabiesclinicsearly-detectionblood-testGeographic Markets
North AmericaEuropeIsraelSwitzerlandMeMed Diagnostics Financials
$223.43M
Total funding
Undisclosed
Capital raised
$93M
Last funding
E
Funding stage
11
Total rounds
11
Investors
Cumulative Funding Raised Over Time ($)
$6.3MAug 2013
$33.3MAug 2015
$126.3MAug 2021
$128.7MSep 2011
$198.7MSep 2018
Private Equity Funding
E Round
Aug 2021
$93M
La Maison Partners, OurCrowd, Phoenix Insurance, Union Tech Ventures
D Round
Sep 2018
$70M
Ping An Ventures, Social Capital, Foxconn Technology Group, Phoenix Insurance
C Round
Aug 2015
$27M
Undisclosed Investor(s)
B Round
Aug 2013
$6.3M
Social Plus Capital , Western Technology Investment, Horizons Ventures
Seed
Sep 2011
$2.35M
Undisclosed Investor(s)
Non-Equity Funding
GrantEvent
Nov 2019
$2.8M
European Innovation Council (EIC)
GrantEvent
Oct 2017
$4.08M
United States Department of Defense
GrantEvent
Jan 2017
$10M
U.S. Department of Defense
GrantEvent
Sep 2016
$2.6M
EU Horizon 2020
GrantEvent
Jul 2015
$3.3M
EU Horizon 2020
GrantEvent
Nov 2013
$2M
EU Horizon 2020
MeMed Diagnostics Lifecycle
Cumulative Funding Raised Over Time
$6.3MAug 2013
$33.3MAug 2015
$126.3MAug 2021
$128.7MSep 2011
$198.7MSep 2018
All Events
E Round
Aug 2021
$93M
La Maison Partners, OurCrowd, Phoenix Insurance, Union Tech Ventures
D Round
Sep 2018
$70M
Ping An Ventures, Social Capital, Foxconn Technology Group, Phoenix Insurance
C Round
Aug 2015
$27M
Undisclosed Investor(s)
B Round
Aug 2013
$6.3M
Social Plus Capital , Western Technology Investment, Horizons Ventures
Seed
Sep 2011
$2.35M
Undisclosed Investor(s)
GrantEvent
Nov 2019
$2.8M
European Innovation Council (EIC)
GrantEvent
Oct 2017
$4.08M
United States Department of Defense
GrantEvent
Jan 2017
$10M
U.S. Department of Defense
GrantEvent
Sep 2016
$2.6M
EU Horizon 2020
GrantEvent
Jul 2015
$3.3M
EU Horizon 2020
GrantEvent
Nov 2013
$2M
EU Horizon 2020
MeMed Diagnostics News
28 articlesInvestegate MeMed Announcements MeMed: Maccabi Healthcare Services announces it is the first HMO in the world to include MeMed BV® test as part of routine care
growth-positive
MeMed raises $93 million to translate the immune system
Israeli healthtech company MeMed has completed a $93 million Series E funding round, bringing its total funding to over $200 million. The funding round included new and existing investors, and the companys valuation has significantly increased. MeMed recently received FDA approval for its MeMed BV test, which helps healthcare providers distinguish between bacterial and viral infections. The company plans to focus on manufacturing in the U.S. and Europe, commercializing its product, and expanding its range of diagnostic solutions. MeMed was founded in 2009 and employs 100 people in Israel, Europe, and the U.S.
Investment
growth-positive
Israeli Firm MeMed Receives FDA Clearance For Infection Test
MeMed Diagnostics has received 510(k) clearance from the FDA for its test, MeMed BV, which can distinguish between bacterial and viral infections. The test analyzes the bodys immune response to infection, allowing for better-informed antibiotic treatment decisions. The FDA clearance is a breakthrough moment for MeMed and its host-response technology. The company plans to ramp up commercial activities in the US to ensure broad availability of its products.
Customers
growth-positive
MeMed's Covid-19 severity test receives its CE Mark to predict severe outcomes
Israeli diagnostic tool company MeMed has received the CE Mark in Europe for its new disease management solution called MeMed Covid-19 Severity. The solution uses machine learning to stratify the risk of severe outcomes from the disease. MeMed aims to help physicians identify Covid-19 patients at risk of severe outcomes and manage future pandemics. The companys long-term vision is to transform the way infections are detected and managed by harnessing the power of the host immune response. MeMed Covid-19 Severity will be available in Europe directly from MeMed and through commercial channels. MeMed has received $130 million in fundraising and grants from investors including the European Innovation Council and OurCrowd.
CustomersPartners
growth-positive
MeMed פיתחה בדיקה שתנבא האם מצבו של חולה קורונה עומד להחמיר
Israeli company MeMed, co-founded by Dr. Eran Eden and Dr. Kfir Oved, has developed a new capability to predict which COVID-19 patients are likely to deteriorate into severe illness. The company reads this information from the immune system response and is the only company currently doing so. MeMeds product is already approved for use in Israel and Europe and is nearing the end of a clinical trial for FDA approval. The company has raised around $100 million in funding and plans to grow by 30-40% in the coming year.
InvestmentExpand
growth-positive
MeMed analyzes complex immune responses to answer simple health questions
MeMed Diagnostics Ltd., an Israeli biotechnology company, has developed innovative technology that analyzes immune responses to infections. Their products, MeMed BV and MeMed Key, use multi-analytes and machine learning algorithms to determine whether a patients infection is viral or bacterial, helping doctors make informed decisions about treatment. The company has received clearance in Israel, Switzerland, and Europe, and is working towards approval in the U.S. MeMeds technology aims to address the overuse of antibiotics and the growing prevalence of antibiotic-resistant bacteria. The company has attracted investors, including Solina Chau from Horizons Ventures. The technology has potential applications in the fight against COVID-19, providing insights into infection severity and patient response to treatment. MeMeds goal is to revolutionize healthcare by improving the understanding of immune system responses to infections.
InvestmentCustomers
growth-positive
DiaSorin and MeMed partner to develop and commercialize novel host immune response based diagnostics solution
DiaSorin and MeMed have formed a strategic partnership to develop and commercialize a novel host immune response-based diagnostics solution. DiaSorin has obtained the rights to commercialize MeMed BV™ test on its LIAISONÒ family of analyzers, which will be available on over 5,000 LIAISONÒ XL and LIAISONÒ XS platforms worldwide. The MeMed BV™ test accurately differentiates between bacterial and viral infections, providing fast and better-informed treatment decisions. The test has been extensively validated and has received regulatory clearances. This partnership will allow DiaSorin to incorporate a cutting-edge test in its menu and expand its innovative technology to customers globally. The partnership is expected to improve patient outcomes and potentially lead to cost savings for the healthcare system.
Partners
growth-positive
Prospective Study Finds Potential Utility of MeMed's Host Immune Technology for Personalizing Treatment of Severe COVID-19 Patients
A prospective study conducted by researchers at Israels Rabin Medical Center in collaboration with MeMed has found that MeMeds host immune technology, specifically the analysis of IP-10, can be useful in managing the care and treatment of severe COVID-19 patients. The study shows that continuous and rapid measurements of IP-10 can predict disease severity, monitor inflammatory status, and personalize treatment strategies for patients with severe COVID-19. The study used MeMeds technology platform, MeMed Key, to measure IP-10 levels in patients. MeMed Key enables highly sensitive measurements of multiple host immune proteins within minutes at the point of need. The findings of the study suggest that further research is warranted in this area.
Customers
growth-positive
Israeli firm advances 15 minute diagnostic test for Covid-19
Israeli diagnostics startup MeMed is working with hospitals to determine how its protein measurement test can enhance Covid-19 care. The test measures the levels of three immune system proteins to distinguish between viral and bacterial infections. MeMed aims to help determine whether individuals exposed to Covid-19 have been infected with a pathogen, the type of pathogen, and the potential severity of the infection. They have received CE Mark clearance for their testing platform in Europe and are now validating various applications of the system in Covid-19 patients.
CustomersPartners
growth-positive
MeMed Receives Regulatory Green Light for Test that can Greatly Reduce Antibiotics Prescriptions
MeMed Diagnostics has received regulatory approval to put its rapid test for identifying viral or bacterial infections on the Israeli and European market. The test can provide results within 15 minutes and helps doctors determine the type of treatment needed, reducing the use of antibiotics. MeMed has raised $100 million from investors including Foxconn and Ping An Global Voyager, and has received grants of about $30 million. The company plans to increase production capacity and expand partnerships with hospitals and HMOs. MeMed is also developing new tests based on testing the immune systems response, including a test for predicting the severity of COVID-19 and a test for detecting infectious diseases before symptoms appear.
CustomersPartnersInvestment
growth-positive
MeMed to predict which COVID-19 patients will worsen
MeMed Diagnostics is developing a diagnostic and prognostic test for early detection of viruses, including coronavirus, and predicting deterioration in the patients situation. The companys technology uses the immune system to diagnose diseases and has already received marketing approval for a device that can detect bacterial or viral diseases within two hours. MeMed is working with partners, including the US army, to develop the test and gather data. The company believes it can also predict whether the disease will worsen and is cooperating with centers around the world to test its predictive capability for COVID-19 patients. MeMed is in touch with health agencies to install the new technology quickly.
CustomersPartners
growth-positive
Is it a virus or a bacteria? Israeli solution wins €2.5M award
MeMed has received €2.5 million from the European Innovation Council (EIC) to accelerate the expansion of its platform to distinguish bacterial and viral infections. The funding will be used to broaden the tests suitability across diverse clinical settings and generate additional clinical validation evidence. MeMeds immune system-based test, called ImmunoXpert, is already cleared for use in the European Union, Switzerland, and Israel.
Investment
growth-positive
MeMed Gets €2.5M to Accelerate Point-of-Care Platform Launch
MeMed has received €2.5 million in funding from the European Innovation Council to accelerate the expansion of its MeMed BV tests applicability. The funding will be used to widen the tests capability to include minimally invasive capillary blood samples and to validate its clinical utility. MeMed will also receive services from the EIC to scale their business and bring their technologies to the market. The company previously raised over $70 million in financing and received a $4.1 million grant from the US Department of Defense.
InvestmentExpand
https://www.ptcommunity.com/wire/memed-named-technology-pioneer-world-economic-forum
https://finance.yahoo.com/news/dtra-commits-additional-funds-memeds-140000548.html
growth-positive
Automated Blood Tests Startup MeMed Raises $70 Million to Expand Offering
MeMed Diagnostics Ltd. has completed a $70 million funding round to launch a new model of its blood testing device and expand its range of tests. The funding round was participated by Ping An Insurance Group Co of China Ltd., OurCrowd Ltd., Li Ka-Shing, Foxconn, and other investors. MeMed develops and markets an automated blood testing device that can diagnose bacterial or viral infections based on specific proteins in the blood. The device provides highly accurate results within minutes to hours, compared to traditional tests that can take days. The funding brings MeMeds total equity raised to $100 million. The company also received grants totaling over $25 million from governmental entities. MeMed plans to use the funding to launch the second generation of its device and hire new employees.
InvestmentExpand
growth-positive
Viral-Bacterial Blood Test Company MeMed Gets Comparative Vote of Confidence
Israeli medical researchers have conducted a study on MeMed Diagnostics viral-bacterial blood testing device and found that it has the potential to reduce antibiotic overuse by almost 90%. MeMed develops and markets an automated blood testing device that can diagnose whether an infection is bacterial or viral based on specific proteins in the blood. The device provides highly accurate results within minutes to hours, compared to traditional tests that can take days. MeMed has raised around $30 million in equity investments and over $25 million in grants from governmental entities. The study, conducted by researchers from Israeli Schneider Childrens Medical Center, compared MeMeds protein-based test to other methods and found it to be more accurate. The study suggests that MeMeds test has the potential to significantly reduce antibiotic overuse.
Customers
growth-positive
New Study Demonstrates Superiority of MeMed's ImmunoXpert™ Over Procalcitonin, CRP, HNL and Additional Biomarkers in Distinguishing Bacterial From Viral Infections
MeMed has published a study comparing the diagnostic performance of its blood test, ImmunoXpert™, to other biomarkers and clinical prediction rules. The study showed that ImmunoXpert™ accurately distinguished between bacterial and viral infections with high sensitivity and specificity. The test outperformed routinely used biomarkers and laboratory parameters, suggesting potential to reduce antibiotic overuse. MeMed is also developing an easy-to-use point-of-care platform to provide rapid results. The study represents an important milestone for MeMeds novel test and its journey towards clinical adoption.
Customers
growth-positive
MeMed Secures Additional Funding From the Department of Defense
MeMed Ltd. has been awarded a $4,079,159 grant by the DoDs Congressionally Directed Medical Research Programs (CDMRP) to support the transition of their prototype point-of-care (POC) platform towards a final product. The grant will be used to set up manufacturing processes and implement cloud connectivity. MeMed recently completed a trilogy of clinical studies that validated their novel blood test for differentiating between bacterial and viral infections in children. The company is now working to expand the menu of tests available on the POC platform, including tests for predicting disease severity and differentiating between sepsis and SIRS.
Investment
growth-positive
Automated Medical Diagnosis Startup Raises $30 Million
Israeli startup MeMed has raised $30 million in funding for its automated blood testing device that can distinguish between bacterial and viral infections. The company has previously received $20 million in development contracts and grants from entities such as the U.S. Department of Defense and the European Commission. MeMeds device tests the response of the immune system and provides quick results, allowing for accurate diagnosis and appropriate treatment. The recent successful clinical trial of the device opens up opportunities for real-world applications and collaborations. MeMed was founded in 2009 and is headquartered in Tirat Carmel, Israel.
Investment
growth-positive
MeMed Completes Trilogy of Clinical Studies with More Than 2,000 Patients Validating First Ever Blood Test to Accurately Distinguish Between Bacterial and Viral Infections
MeMed has announced positive results from a clinical study validating its blood test, ImmunoXpert, which accurately distinguishes between bacterial and viral infections in children. The study, called PATHFINDER, is the third in a trilogy of clinical studies conducted by MeMed. The results of the study, along with additional data from early access medical centers, will drive market adoption and solidify MeMed as a leader in immune-based diagnostics. The blood test demonstrated 94% sensitivity and 90% specificity in distinguishing between bacterial and viral patients. It outperformed routine laboratory parameters and reduced both false negatives and false positives. MeMed is now developing a point-of-care platform for the test with support from the US Department of Defense.
Customers
growth-positive
http://www.jpost.com/Business-and-Innovation/Tech/Israeli-firm-US-Department-of-Defense-to-fight-infectious-disease-together-488470
Israeli company MeMed is partnering with the United States Department of Defense to develop a second-generation diagnostic system for distinguishing between bacterial and viral infections. The new system, which will be capable of providing results within 15 minutes, aims to address the global threat of antibiotic-resistant bacteria. MeMeds first-generation ImmunoXpert system is already on the market. The company received a $9.2 million contract from the Defense Threat Reduction Agency to revamp its technology. MeMeds technology uses three proteins in the blood to diagnose infections, and the second-generation model will be easier to use and more efficient.
PartnersInvestment
growth-positive
MeMed Awarded $9.2M Contract by US Department of Defense
MeMed Ltd. has been awarded a contract by the Defense Threat Reduction Agency (DTRA) worth up to $9.2M. The contract will fund the completion of MeMeds point of care platform for distinguishing bacterial from viral infections. The companys second-generation test will allow rapid testing at the point of care within minutes. MeMeds CEO, Eran Eden, expressed excitement about the contract and stated that it positions MeMed as a world leader in immune-based diagnostics of infectious diseases. The collaboration with DTRA and other international stakeholders will facilitate the global availability of MeMeds tests aimed at combating antimicrobial resistance. MeMeds first-generation test, ImmunoXpert, is already in use and has been validated in thousands of patients. The second generation of the test involves the development of a new point of care platform that is easy to use and takes only 15 minutes.
Investment
growth-positive
Does your child really need that antibiotic?
A clinical study published in Lancet Infectious Diseases confirmed that MeMeds blood test, ImmunoXpert, accurately distinguishes between bacterial and viral infections in children. The test outperformed routine tests and has the potential to reduce antibiotic overuse and combat bacterial resistance. MeMed is collaborating on multi-center clinical studies and plans to conduct studies in the United States in 2017.
Customers
growth-positive
Lancet Infectious Diseases Publishes Independent Double-Blind Study Validating MeMed's Immunoxpert™ Blood Test's Ability to Accurately Distinguish Between Bacterial and Viral Infections in Children
MeMed Ltd. announced the publication of the results from a clinical study that confirms the accuracy and effectiveness of their blood test, ImmunoXpert, in distinguishing between bacterial and viral infections in children. The study showed that ImmunoXpert significantly outperformed routine tests and has the potential to reduce antibiotic overuse and combat bacterial resistance. The test looks at the immune system to identify markers that indicate the type of infection a patient is fighting. MeMed is collaborating with clinical thought leaders on further studies and plans to conduct clinical studies in the U.S. in 2017. The company aims to provide rapid and accurate diagnostic solutions for infectious diseases and inflammatory disorders.
Customers
growth-positive
New diagnostic test distinguishes bacterial from viral infections
Israeli startup MeMed has developed two products, ImmunoXpert and ImmunoPoC, to address the global health crisis of antibiotic overuse. ImmunoXpert is currently used by hospitals in the EU, Switzerland, and Israel to determine whether an infection is bacterial or viral. MeMed has received significant investments and prizes, including funding from blue-chip VCs and grants from the European Commission. The company plans to use the funds for clinical studies in Europe and expand into other markets, including the US and Latin America. MeMed is ahead of its competitors and has a multidisciplinary team working on developing additional tools in the future.
InvestmentExpand
€2.3 Million Award by European Commission Will Support Deployment of ImmunoXpert™ to Reduce Antibiotic Misuse in Hospitals
growth-positive
MeMed swiftly diagnoses if a disease is viral or bacterial
MeMed, an Israeli medical device company, has developed a diagnostic tool that can determine whether a patient has a bacterial or viral infection within two hours. The tool, which has received regulatory approval in Israel and Europe, is currently being used in pilot programs at several hospitals. The company recently won a €3 million grant from the European Union’s Horizon 2020 program, which funds life sciences companies with innovative technology. MeMed plans to begin clinical trials in the US and is also interested in the Chinese market. The company has raised an undisclosed amount of funding from investors including Hanina Brandes, Social + Capital, and Horizon Ventures.
InvestmentExpand
MeMed Diagnostics Team
Employee Info
| Employees (range) | 51-200 |
| Exact count | 105 |
| Team members | 5 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 12 classification IDs that could be used for matching.
MeMed Diagnostics Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 100/100 |
| Missing | markets |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 514288885 |
| Crunchbase | memed |
| Phone | +97248500302 |
| Creator | Rebecca Mack |
| Creator email | rebeccamack26@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2022-08-26T00:00:00.000Z |
| Created | 2014-06-24T00:00:00.000Z |
| Claimed | Yes |